IO Biotech, Inc.

Filter

År

Typ

Språk

Rensa

2024-07-25 22:05:00 IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 -0,74%

2024-05-23 14:30:00 IO Biotech to Present at Jefferies Global Healthcare Conference -0,75%

2024-05-14 13:55:00 IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights +2,13%

2024-04-24 22:30:00 IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -0,68%

2024-04-09 18:00:00 IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 +4,55%

2024-04-05 14:30:00 IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer -3,66%

2024-03-06 22:11:01 IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting +2,47%

2024-03-05 22:40:01 IO Biotech Announces 2023 Fourth-Quarter and Year-End Results -3,57%

2024-02-26 22:05:00 IO Biotech to Present at 44th Annual Cowen Health Care Conference +2,65%

2023-12-21 14:30:00 IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial -1,35%

2023-11-13 14:12:16 IO Biotech Announces 2023 Third Quarter Results +2,30%

2023-11-08 22:30:00 IO Biotech Announces Participation in Upcoming Investor Conferences -2,73%

2023-11-01 13:30:00 IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting +1,30%

2023-10-03 22:30:00 IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting +10,22%

2023-09-12 14:05:00 IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer -13,20%

2023-09-06 14:35:00 IO Biotech Announces Participation in Upcoming Investor Conferences -4,37%

2023-08-11 14:30:00 IO Biotech Announces 2023 Second Quarter Results 0,00%

2023-08-11 14:05:00 IO Biotech Appoints Heidi Hunter to its Board of Directors 0,00%

2023-08-08 14:05:00 IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023 0,00%

2023-08-07 14:30:12 IO Biotech, Inc. Announces $75 Million Private Placement Financing -1,60%

2023-07-28 14:05:00 IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center -3,12%

2023-07-25 22:05:00 IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer +3,31%

2023-07-18 22:05:00 IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer 0,00%

2023-06-14 14:00:00 IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone -26,48%

2023-06-01 14:30:00 IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead -3,85%

2023-05-30 22:35:00 IO Biotech to Present at the Jefferies Healthcare Conference +2,22%

2023-05-11 22:05:00 IO Biotech Announces 2023 First-Quarter Results +9,69%

2023-03-14 21:11:47 IO Biotech Announces 2022 Fourth-Quarter and Year-End Results +1,39%

2023-02-22 13:00:00 IO Biotech to Participate in March 2023 Investor Conferences -2,61%

2023-01-23 14:00:00 IO Biotech Announces Appointment of Devin Smith as General Counsel +1,02%

2023-01-09 13:05:46 IO Biotech Provides Business Update -2,00%

2022-11-09 22:07:58 IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting +1,62%

2022-11-09 22:05:00 IO Biotech Announces Third Quarter Results for 2022 +1,62%

2022-11-03 13:00:00 IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors +2,04%

2022-10-31 13:00:00 IO Biotech to Participate in the Jefferies London Healthcare Conference +2,49%

2022-10-13 22:05:00 IO Biotech Announces Appointment of New Chief Financial Officer +4,95%

2022-10-05 14:05:00 IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting -6,98%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

IO Biotech, Inc.

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden